Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.45 |
| ▸ | NPC1 | O15118 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | ECE1 | P42892 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | KDM4B | O94953 | 1/20 | 0.33 |
| ▸ | KDM5C | P41229 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2522754 | 1.00 | RAB9A (0.45) | RAB9ANPC1SMN1; SMN2ABL1KDM4E | |
| SCHEMBL2524482 | 0.84 | RAB9A (0.43) | RAB9ANPC1SMN1; SMN2ABL1KDM4E | |
| SCHEMBL2524485 | 0.84 | RAB9A (0.43) | RAB9ANPC1SMN1; SMN2ABL1KDM4E | |
| SCHEMBL2517575 | 0.79 | TSHR (0.47) | RAB9ANPC1SMN1; SMN2MAPTGAA | |
| SCHEMBL2517577 | 0.79 | TSHR (0.47) | RAB9ANPC1SMN1; SMN2MAPTGAA | |
| SCHEMBL2588355 | 0.72 | RAB9A (0.50) | RAB9ANPC1SMN1; SMN2ABL1KDM4E | |
| SCHEMBL2588353 | 0.72 | RAB9A (0.50) | RAB9ANPC1SMN1; SMN2ABL1KDM4E | |
| SCHEMBL2527562 | 0.72 | ADORA2A (0.42) | RAB9ANPC1SMN1; SMN2ABL1MAPT | |
| SCHEMBL2527559 | 0.72 | ADORA2A (0.42) | RAB9ANPC1SMN1; SMN2ABL1MAPT | |
| SCHEMBL15047223 | 0.72 | LMNA (0.53) | RAB9ANPC1SMN1; SMN2MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2558467-B1 | ARYL-/HETEROARYL-CYCLOHEXENYL-TETRAAZABENZO[E]AZULENES AS VASOPRESSIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2017-05-17 | — | — | EP | disclosed |
| US-8461151-B2 | Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes | HOFFMANN-LA ROCHE INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8461151-B2 | Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes | HOFFMANN-LA ROCHE INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8461151-B2 | Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes | HOFFMANN-LA ROCHE INC. (US) | 2013-06-11 | — | — | US | disclosed |
| EP-2558467-A1 | ARYL - /HETEROARYL - CYCLOHEXENYL - TETRAAZABENZO [E]AZULENES AS VASOPRESSIN ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011128265-A1 | ARYL - /HETEROARYL - CYCLOHEXENYL - TETRAAZABENZO [E] AZULENES AS VASOPRESSIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-20 | — | — | WO | disclosed |
| US-20110251183-A1 | ARYL-/HETEROARYL-CYCLOHEXENYL-TETRAAZABENZO[E]AZULENES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-13 | — | — | US | disclosed |
| US-20110251183-A1 | ARYL-/HETEROARYL-CYCLOHEXENYL-TETRAAZABENZO[E]AZULENES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-13 | — | — | US | disclosed |
| US-20110251183-A1 | ARYL-/HETEROARYL-CYCLOHEXENYL-TETRAAZABENZO[E]AZULENES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251183-A1 | ARYL-/HETEROARYL-CYCLOHEXENYL-TETRAAZABENZO[E]AZULENES | OXTR, AVPR1B, AVPR1A | RAB9A 1034/4885NPC1 1309/4885SMN1; SMN2 3577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.